Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06626269
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HORIZON
Brief Summary:
The immune system may be involved in the recognition and destruction of tumor cells or cells undergoing transformation It is also currently accepted that the quality of immune responses can influence the evolution of cancers after chemotherapy
In this context it is possible to assess the presence of specific T cells in patients39 blood and to correlate the presence of specific memory lymphocytes with the quality of long-term clinical protection
The analysis of immune responses can also be based on i analysis of the tumor microenvironment analysis of surgical samples or biopsies or ii analysis of molecules secreted in plasma
Today the immunotherapies can generate clinical responses in several cancers for 15 to 25 of patients with melanomas bladder lung kidney or gastric cancers But the development of these drugs raises two unresolved questions i what immunological parameters predict the efficacy of these treatments ii why do some cancers remain refractory to the efficacy of these immunomodulatory drugs It is therefore necessary to identify biomarkers for prognostic stratification and monitoring of patients treated by immunotherapy
The primary objective of our research team is to identify biomarkers related to the immune system or tumor microenvironment in order to better define patient eligibility criteria for immunotherapy strategies
In this context it is possible to assess the presence of specific T cells in patients39 blood and to correlate the presence of specific memory lymphocytes with the quality of long-term clinical protection
The analysis of immune responses can also be based on i analysis of the tumor microenvironment analysis of surgical samples or biopsies or ii analysis of molecules secreted in plasma
Today the immunotherapies can generate clinical responses in several cancers for 15 to 25 of patients with melanomas bladder lung kidney or gastric cancers But the development of these drugs raises two unresolved questions i what immunological parameters predict the efficacy of these treatments ii why do some cancers remain refractory to the efficacy of these immunomodulatory drugs It is therefore necessary to identify biomarkers for prognostic stratification and monitoring of patients treated by immunotherapy
The primary objective of our research team is to identify biomarkers related to the immune system or tumor microenvironment in order to better define patient eligibility criteria for immunotherapy strategies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None